← Oncology Approval Tracker

FDA DECISION ·

Retevmo

selpercatinib · Eli Lilly

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Sep 21, 2022

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with metastatic non-small cell lung cancer with a RET gene fusion.

LAMPGEN ANALYSIS

Why it matters

Introduced a selective RET inhibitor for RET fusion-positive lung cancer under accelerated approval.

What research teams should watch

Use fusion-capable molecular testing and monitor blood pressure and liver tests during treatment.

PRIMARY RECORDS

Sources